

## Commentary on: “Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk”

Word Count: 852 text including figure legend

Pages (with bibliography figure and figure legend): 9

While it is of critical importance to rapidly publish the latest findings on COVID-19, recent high profile retractions of COVID-19 reports (Mehra, Desai, Kuy, Henry, & Patel, 2020; Mehra, Desai, Ruschitzka, & Patel, 2020), reminds us that it is important to be vigilant for the accuracy of this literature.

A recent paper published in *Molecular Pharmacology* suggests that there is an interaction of nicotinic cholinergic receptors and angiotensin-converting enzyme 2 (ACE2) in the brain that predisposes smokers to increased susceptibility to infection of the brain by SARS-CoV-2 (Kabbani & Olds, 2020), above and beyond the general damage of smoking to the airways . However, the purported mechanism for this toxicity is unsubstantiated and does not accurately reflect current knowledge of predisposing factors for COVID-19 toxicity. This commentary addresses some of these issues.

ACE2 is a protein that is considered to be part of the renin-angiotensin system as well as the primary receptor by which SARS-CoV-2 enters cells (Figure) (Hoffmann, et al., 2020). And, while there is little doubt that smoking nicotine-containing tobacco products predisposes smokers to increased disease susceptibility, this predisposition arises from adverse effects of nicotine on the cardiovascular system

<https://www.cdc.gov/tobacco/campaign/tips/diseases/heart-disease-stroke.html> (accessed 4/25/20) as well as the inhalation of particulate and volatile substances that directly injure lung cells [https://www.cdc.gov/tobacco/campaign/tips/diseases/index.html?s\\_cid=OSH\\_tips\\_D9389](https://www.cdc.gov/tobacco/campaign/tips/diseases/index.html?s_cid=OSH_tips_D9389)

(accessed 4/25/20) (Oakes, Fuchs, Gardner, Lazartigues, & Yue, 2018). Specifically, it has been shown that both acute and subacute nicotine administration to female rats increased blood-brain-barrier permeability by altering tight junction proteins of the cerebral microvessel endothelial cells (Hawkins, et al., 2004), an effect independent of ACE2.

Linking increased brain susceptibility to SARS-CoV-2 infection with smoking "...based upon known functional interactions between the nicotinic receptor and ACE2." (Kabbani & Olds, 2020) is unsubstantiated, as none of the papers cited by these authors for demonstrating colocalization of NACHRs on the same brain cells as ACE2 (Changeux, 2010; Nordman, Muldoon, Clark, Damaj, & Kabbani, 2014; Tolu, et al., 2013) mention the word angiotensin or the acronym ACE2 as being associated with nicotinic receptor-containing cells. Of note, colocalization of NACHRs and components of the RAS in bronchial and alveolar epithelial cells in the lungs has been reported (Oakes, et al., 2018).

A subsequent claim for an association of NACHRs and ACE2 comes from a concurrent publication by these authors (Olds & Kabbani, 2020) "nicotine stimulation of the nAChR can increase ACE2 expression within them (Olds and Kabbani, 2020)." They cite a medRxiv paper by Cai et al., 2020 <https://www.preprints.org/manuscript/202002.0051/v1> demonstrating that tobacco smoking is associated with increased ACE2 gene expression. However, a peer-reviewed manuscript from this same author noted that it has not been determined whether the 25% increase in ACE2 gene expression is due to nicotine, or the other components of inhaled tobacco smoke (Cai, Bosse, Xiao, Kheradmand, & Amos, 2020). Moreover, nicotine has been shown to decrease ACE2 expression (Oakes, et al., 2018), which contradicts the hypothesis that nicotine increases ACE2 expression (Kabbani & Olds, 2020). This implies that it is the other components of tobacco smoke, not nicotine, that increase ACE2 expression.

Later in the manuscript the authors write “Interactions between nAChRs and ACE2 have been studied in several of these [brain] regions including the ventrolateral medulla (Deng et al., 2019)” (Kabbani & Olds, 2020). However, Deng et al., 2019 described changes in acetylcholine in this brain region in relation to ACE2 expression, and that paper does not mention NACHRs at all.

It is regrettable that the companion paper (Olds & Kabbani, 2020) cited by Kabbani and Olds (Kabbani & Olds, 2020) also contains questionable statements, e.g., “ACE2 appears to play both protective and pathogenic roles within RAS pathways, and its direct mechanisms of function in cells remain less understood [7,8].” (Olds & Kabbani, 2020). ACE2 is an extremely well characterized protein (Feng, Xia, Santos, Speth, & Lazartigues, 2010; Raizada & Ferreira, 2007; Soler, Wysocki, & Batlle, 2008; Turner, Hiscox, & Hooper, 2004; Turner & Hooper, 2002) and has been overwhelmingly recognized as only playing a beneficial role within the renin-angiotensin system (RAS) (R. A. Santos, Ferreira, Verano-Braga, & Bader, 2013).

There is a considerable body of literature regarding the interaction of SARS-CoV-2 with the RAS, in particular ACE2, which serves as its receptor for entry into cells (Hoffmann, et al., 2020). Most published papers and cardiovascular medicine societies (Gurwitz, 2020; Reynolds, et al., 2020; Speth, 2020a, 2020b, 2020c; Sriram & Insel, 2020; Vaduganathan, et al., 2020) support the continued use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) based upon the predominant beneficial effects of reducing the ability of angiotensin II to promote inflammation acting via the AT<sub>1</sub> receptor (Ranjbar, et al., 2019). ACE2 by metabolizing Ang II and forming angiotensin 1-7, which has anti-inflammatory actions via its receptor Mas (R. A. S. Santos, et al., 2018) may help to

minimize the cytokine storm (Annweiler, et al., 2020; Mahmudpour, Roozbeh, Keshavarz, Farrokhi, & Nabipour, 2020) that exacerbates lung damage associated with COVID-19.

The adverse effects of smoking on outcomes of COVID-19 infection are indisputable. However, it is necessary to accurately determine what aspect of smoking and which target tissues mediate this increase in morbidity and mortality.

The author reports no conflicts of interest.

There was no funding associated with the preparation of this manuscript.

**Acknowledgment:** The author thanks Drs. Eric Lazartigues and Kathryn Sandberg for previewing and providing comments on this communication.

Robert C. Speth, Ph.D., FAAAS, FAHA  
Professor  
Department of Pharmaceutical Sciences  
College of Pharmacy  
Nova Southeastern University  
Fort Lauderdale, FL 33328  
Adjunct Professor  
Department of Pharmacology and Physiology  
School of Medicine  
Georgetown University  
Washington, D.C. 20057  
Email: rs1251@nova.edu  
Phone: 954-262-1330  
Fax: 954-262-2278  
ORCID ID: 0000-0002-6434-2136

## References

Annweiler, C., Cao, Z., Wu, Y., Faucon, E., Mouhat, S., Kovacic, H., & Sabatier, J. M. (2020).  
Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat

COVID-19 Diseases in SARS-CoV-2-infected patients. *Infect Disord Drug Targets*. May 17. doi: 10.2174/1871526520666200518073329.

Cai, G., Bosse, Y., Xiao, F., Kheradmand, F., & Amos, C. I. (2020). Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med*. Jun 15;201(12):1557-1559. doi: 10.1164/rccm.202003-0693LE.

Changeux, J. P. (2010). Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. *Nat Rev Neurosci*, 11, 389-401.

Feng, Y., Xia, H., Santos, R. A., Speth, R., & Lazartigues, E. (2010). Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. *Exp. Physiol*, 95, 601-606.

Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res*. Mar 4:10.1002/ddr.21656. doi: 10.1002/ddr.21656

Hawkins, B. T., Abbruscato, T. J., Egletton, R. D., Brown, R. C., Huber, J. D., Campos, C. R., & Davis, T. P. (2004). Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution. *Brain Research*, 1027, 48-58.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.

Kabbani, N., & Olds, J. L. (2020). Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. *Mol Pharmacol*, 97, 351-353.

- Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020). COVID-19 cytokine storm: The anger of inflammation. *Cytokine*, *133*, 155151.
- Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D., & Patel, A. N. (2020). Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med*. Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Retracted
- Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet* . 2020 May 22;S0140-6736(20)31180-6. doi: 10.1016/S0140-6736(20)31180-6.
- Nordman, J. C., Muldoon, P., Clark, S., Damaj, M. I., & Kabbani, N. (2014). The alpha4 nicotinic receptor promotes CD4+ T-cell proliferation and a helper T-cell immune response. *Mol Pharmacol*, *85*, 50-61.
- Oakes, J. M., Fuchs, R. M., Gardner, J. D., Lazartigues, E., & Yue, X. (2018). Nicotine and the renin-angiotensin system. *Am J Physiol Regul Integr Comp Physiol*, *315*, R895-r906.
- Olds, J. L., & Kabbani, N. (2020). Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? *Febs j*. Mar 18:10.1111/febs.15303. doi: 10.1111/febs.15303.
- Raizada, M. K., & Ferreira, A. J. (2007). ACE2: a new target for cardiovascular disease therapeutics. *J Cardiovasc Pharmacol*, *50*, 112-119.
- Ranjbar, R., Shafiee, M., Hesari, A., Ferns, G. A., Ghasemi, F., & Avan, A. (2019). The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases. *J Cell Physiol*, *234*, 2277-2295.

- Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., Katz, S. D., Fishman, G. I., Kunichoff, D., Chen, Y., Ogedegbe, G., & Hochman, J. S. (2020). Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. *New England Journal of Medicine*. Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975.
- Santos, R. A., Ferreira, A. J., Verano-Braga, T., & Bader, M. (2013). Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. *J Endocrinol*, 216, R1-r17.
- Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018). The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol Rev*, 98, 505-553.
- Soler, M. J., Wysocki, J., & Battle, D. (2008). Angiotensin-converting enzyme 2 and the kidney. *Exp.Physiol*, 93, 549-556.
- Speth, R. C. (2020a). Angiotensin II administration to COVID-19 patients is not advisable. *Crit Care*, 24, 296.
- Speth, R. C. (2020b). Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic. *J Travel Med*. May 18;27(3):taaa045. doi: 10.1093/jtm/taaa045.
- Speth, R. C. (2020c). Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections. *Drug Dev Res*. Apr 17:10.1002/ddr.21672. doi: 10.1002/ddr.21672

- Sriram, K., & Insel, P. A. (2020). Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. *Clin Pharmacol Ther.* Aug;108(2):236-241. doi: 10.1002/cpt.1863
- Tolu, S., Eddine, R., Marti, F., David, V., Graupner, M., Pons, S., Baudonnat, M., Husson, M., Besson, M., Reperant, C., Zemdegs, J., Pages, C., Hay, Y. A., Lambolez, B., Caboche, J., Gutkin, B., Gardier, A. M., Changeux, J. P., Faure, P., & Maskos, U. (2013). Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement. *Mol Psychiatry*, 18, 382-393.
- Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004). ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol.Sci.*, 25, 291-294.
- Turner, A. J., & Hooper, N. M. (2002). The angiotensin-converting enzyme gene family: genomics and pharmacology. *Trends Pharmacol.Sci.*, 23, 177-183.
- Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020). Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *New England Journal of Medicine.* Apr 23;382(17):1653-1659. doi: 10.1056/NEJMs2005760



**Legend for Figure:** Simplified diagram of renin-angiotensin system. SARS-CoV-2 spike protein S1 domain binds to the extracellular domain of ACE2 leading to internalization of the SARS-CoV-2-ACE2 complex which decreases ACE2 expression on cell membranes. ACE2, and AT<sub>1</sub> and Mas receptors are present in lung and kidney, two of the tissues most adversely affected by SARS-CoV-2 infection. Angiotensin 1-5 has no established function. BP is blood pressure. Liver image from <https://www.pcosnutrition.com/fattyliver/> Kidney image is from <https://www.alportsyndrome.org/stages-of-kidney-disease/> Lung image is from <https://www.dreamstime.com/stock-images-pulmonary-hypertension-image27276044> SARS-CoV-2 image from <https://www.cdc.gov/media/subtopic/images.htm>

